‘How to’ – Stability Studies

Oncology drugs, which are often life-saving medications, require rigorous stability studies to ensure their safety, efficacy, and quality throughout their shelf life. The US FDA and EMA have specific guidelines that outline the stability requirements for these high-risk drugs. Implementing these stability studies is crucial for compliance with regulatory standards and to ensure patient safety. This guide provides a comprehensive approach to conducting stability studies for oncology drugs under the guidelines set by the US FDA and EMA.
Click to read the full article.

Ophthalmic products, including eye drops and ointments, require specific stability testing to ensure their safety, efficacy, and quality throughout their shelf life. These products are particularly sensitive to microbial contamination and environmental factors, making rigorous stability testing crucial. This guide outlines the steps for conducting stability testing for ophthalmic products under the guidelines of regulatory authorities like the US FDA, EMA, and WHO.
Click to read the full article.

A well-prepared stability testing plan is essential for ensuring that pharmaceutical products maintain their safety, efficacy, and quality throughout their shelf life. Compliance with global regulatory requirements, such as those set by the US FDA, EMA, and WHO, is crucial for gaining market approval and ensuring product integrity. This guide outlines the steps to prepare a stability testing plan that meets global regulatory standards.
Click to read the full article.

Complex generic drugs, which include formulations such as liposomal drugs, injectables, and transdermal systems, require rigorous stability studies to ensure their safety, efficacy, and quality throughout their shelf life. The US FDA provides specific guidelines for conducting stability studies for these products. This guide outlines the steps to conduct stability studies for complex generic drugs in compliance with FDA requirements.
Click to read the full article.

Stability testing is a critical component of the drug development process, ensuring that Active Pharmaceutical Ingredients (APIs) and finished drug products maintain their intended quality, safety, and efficacy over time. The ICH Q1A(R2) guidelines provide a harmonized approach to conducting stability studies across different regions. This guide outlines the steps for implementing ICH Q1A(R2) for stability testing of APIs and drug products, ensuring compliance with global regulatory requirements.
Click to read the full article.

Breakthrough therapy drugs are designated by the FDA for expedited development and review due to their potential to provide substantial improvement over existing therapies for serious conditions. These drugs require specific stability testing to ensure their safety, efficacy, and quality throughout their expedited lifecycle. This guide outlines the steps to address stability testing requirements for breakthrough therapy drugs under FDA guidelines.
Click to read the full article.

Biologics, including biosimilars, are complex molecules that require stringent stability testing to ensure their safety, efficacy, and quality. Stability studies for biosimilars must demonstrate that the product remains comparable to its reference biologic under specified storage conditions. This guide provides a detailed approach to conducting stability testing for biologics in compliance with biosimilar regulatory guidelines.
Click to read the full article.

Non-oral dosage forms, such as injectables, inhalers, transdermal patches, and ophthalmic solutions, present unique challenges in stability testing due to their distinct formulations, delivery mechanisms, and storage conditions. Ensuring compliance with regulatory guidelines, such as those provided by the US FDA, EMA, and WHO, is essential for maintaining the safety, efficacy, and quality of these products throughout their shelf life. This guide provides a step-by-step approach to implementing stability testing for non-oral dosage forms in accordance with global regulatory standards.
Click to read the full article.

Drugs with a narrow therapeutic index (NTI) have a small margin between therapeutic and toxic doses, making precise and rigorous stability testing essential to ensure patient safety. The US FDA provides specific guidelines for conducting stability studies on NTI drugs to maintain their efficacy, safety, and quality throughout their shelf life. This guide outlines the steps to conduct stability studies for NTI drugs in compliance with FDA guidelines.
Click to read the full article.

High-risk drug products, such as controlled substances, cytotoxic agents, and biologics, require stringent stability testing to ensure their safety, efficacy, and quality. Regulatory authorities, including the US FDA, EMA, and WHO, have established specific guidelines for stability testing of high-risk drug products. This guide outlines the steps to implement stability testing for high-risk drug products in compliance with these regulations.
Click to read the full article.